Abstract: ObjectiveTo explore the effectiveness of epidermal growth factor receptor (EGFR)tyrosine kinase inhibitors (TKIs) in nonsmall cell lung cancer (NSCLC) patients with EGFR double mutations containing rare mutations. MethodsFrom March 2007 to January 2017, NSCLC patients with EGFR double mutations containing rare mutations confirmed by histopathology and EGFR mutation detections at Renmin Hospital of Wuhan University, Zhongnan Hospital of Wuhan University and Hubei Cancer Hospital were enrolled. According to the mutation types, patients were divided into double activating mutations group and activating mutations with insensitive mutations group. The effectiveness of TKIs in NSCLC patients with EGFR double mutations containing rare mutations and different mutation types was analysis. ResultsAmong the 2 637 NSCLC patients underwent EGFR mutation detections, 19 patients were confirmed as EGFR double mutations containing rare mutations. Fifteen patients received EGFRTKIs therapy, the objective response rate (ORR), disease control rate (DCR) and median progression free survival (PFS) were 46.7% (7/15), 73.3% (11/15) and 8.1 months, respectively. In patients with double activating mutations, two patients had partial response (PR), one patient had a stable disease (SD). In the activating mutations with insensitive mutations group, five patients had PR, three patients had SD, four patients had no effect. ConclusionPatients with EGFR double mutations containing rare mutations have a general response to EGFRTKIs, and this result can provide a reference for the treatment of those patients.

Key words: Genes, erbB-1, Carcinoma, non-small-cell lung, Protein kinase inhibitors